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OBJECTIVES: Patients undergoing surgery for hip frac-
ture are in the highest category of risk for postoperative
venous thromboembolism, but data on thromboprophy-
laxis in these patients were scarce. Fondaparinux, a new
synthetic selective factor Xa inhibitor proved to be more
effective than enoxaparin in preventing venous throm-
boembolism in these patients and was equally safe. We
evaluated its cost-effectiveness relative to enoxaparin 
over a period of ﬁve years post-surgery. METHODS: We
modelled the impact of fondaparinux based on 7-day 
prophylaxis on patient outcomes and costs to the UK
National Health Service (NHS). Outcomes are throm-
boembolic events (symptomatic deep vein thrombosis,
pulmonary embolism), and long term complications
(recurrences, post thrombotice syndrome), and death.
Probabilities for efﬁcacy and safety outcomes were
derived from randomised clinical trials comparing enoxa-
parin with fondaparinux, and from a review of the liter-
ature. Resource consequences were estimated from a
survey of UK hospitals and a panel of clinical experts.
Costs were estimated using mean national costs to the
NHS. RESULTS: In a hypothetical cohort of 1000
patients, fondaparinux is estimated to prevent 23 addi-
tional thromboembolic events (clinical VTE) and 6 deaths
compared to enoxaparin, with savings fully compensat-
ing added costs of prophylaxis by day 30 (break-even
point). Total savings for the cohort would be £29,000 at
5 years. These ﬁndings are robust to wide variations in
key assumptions in the model. CONCLUSIONS: Com-
pared with enoxaparin, fondaparinux is a cost-effective
and dominant strategy in prophylaxis against venous
thromboembolism following hip fracture surgery. Bene-
ﬁts of using fondaparinux begin early following surgery,
with savings increasing over time.
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OBJECTIVE: The PCI-CURE study demonstrated that
clopidogrel compared to placebo, both groups receiving
standard therapy including ASA reduces the risk of major
cardiovascular events in patients with ACS undergoing
PCI. The purpose of this analysis was to evaluate the cost
per event avoided in Austria, Belgium, Italy, Spain, and
Switzerland. METHODS: The composite outcome used
for the cost-effectiveness analysis was the difference in
occurrences of all cardiovascular deaths, myocardial
infarctions, and strokes. Costs of hospitalization, pro-
cedures, comedications and study drug were calculated
based on resource utilization reported for all patients
undergoing PCI in the CURE study. Hospitalization 
costs were evaluated through a Diagnosis Related Group
approach in all countries. Unit costs were developed in
each country and applied to all patients of the CURE
study. Cost-effectiveness was expressed as the cost per
event avoided, in analogy with previously published eval-
uations in this area. The time horizon was that of the 
clinical trial (12 months). RESULTS: The occurrence of
the composite outcome was signiﬁcantly lower in the
clopidogrel arm compared to placebo (11.65% versus
15.17%). For every 1000 patients treated with clopido-
grel 35 additional atherothrombotic events were avoided.
The total cost of managing a patient with ACS undergo-
ing PCI ranged from €5,728 to €13,604 in the placebo
arm depending on the country. This cost was increased
by +1.2% to +4.9% in the clopidogrel arm. The cost 
of clopidogrel was partly offset by savings due to less
severe main diagnosis during hospitalizations. The incre-
mental cost per patient ranged from €166 to €390. This
resulted in a cost per cardiovascular event avoided
ranging from €4,732 to €11,065, which is better com-
pared to other interventions in this area. CONCLUSION:
Clopidogrel in patients with ACS undergoing a PCI is
cost-effective and results are very consistent across 
European countries.
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OBJECTIVES: To identify and to explain the possible dif-
ferences in resource use for the treatment of chronic heart
failure (CHF) in France (F), Germany (G), Italy (I), the
Netherlands (NL), Spain (S), and the United Kingdom
(UK). METHODS: MAHLER was a multi-centric obser-
vational (non-interventional) study on the medical man-
agement, the health care resource use and the cost of
CHF. A total of 1421 NYHA (New York Heart Associa-
tion) class II to IV patients were included and were
prospectively followed over 6 months. The frequencies of
patients using a speciﬁc resource and the mean number
of uses were computed for each country. Predictors of
